2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...

It has been a shaky time for healthcare stocks, but that only presents a buying opportunity. The Health Care Select Sector ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Amgen (AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of ...

Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

Telangana has attracted 141 life sciences investments totaling 36,000 crore, expected to create 51,000 direct jobs. With a ...

Telangana has attracted 141 life sciences investments totaling 36,000 crore, expected to create 51,000 direct jobs. With a ...

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...